Instruments and Solutions to Accelerate Cell Therapy Development


Agilent - 408361

Innovative approaches to improve in vivo efficacy

Genetically modified immune cell therapies use cells that have been engineered to improve their abilities to fight disease.  In the case of cancer, transgenic chimeric antigen receptors (CARs), T cell receptors (TCRs), and other enhancements are designed to improve tumor-specific immunogenicity and to enhance tumor cell killing. 

Despite early successes, there are limitations that complicate the development, testing, and manufacturing of cell therapies. These include:

  • Lack of standard potency assays to measure biological activity and efficacy 

  • Suboptimal tumor cell models and difficulties in solid tumor cell targeting

  • Challenges in assessing metabolic status to improve immune cell activities

This eBook focuses on the latest instruments, tools, and techniques designed to address these challenges and accelerate immune cell therapy development and testing.



agilent-logo-s png



download this free ebook to learn more

Agilent - 408361 cover image